Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.

Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.
复制标题

使用抗 Tac(一种针对白细胞介素 2 受体的单克隆抗体)治疗人 T 细胞淋巴病毒 I 诱导的成人 T 细胞白血病患者。

DOI:
10.1182/blood.v72.5.1805.1805
复制
发表时间:
1988
期刊:
影响因子:
20.3
通讯作者:
D. Longo
D. Longo
中科院分区:
医学1区
文献类型:
--
作者:
T. Waldmann;C. Goldman;K. Bongiovanni;S. Sharrow;M. Davey;K. Cease;S. Greenberg;D. Longo

文献摘要

参考文献

被引文献

相似文献

人T细胞嗜淋巴细胞病毒I(HTLV-I)诱导的成人T细胞白血病(ATL)细胞组成型表达由抗Tac单克隆抗体(MoAb)鉴定的白细胞介素-2(IL-2)受体,而正常静息细胞不表达。这一观察结果为静脉注射抗Tac治疗9例ATL患者的试验提供了科学依据。这些患者没有出现不良反应,血液中的正常成分也没有减少,9名患者中只有1名产生了抗Tac单克隆抗体的抗体。通过常规血液学检查、循环细胞免疫荧光分析、HTLV-I前病毒整合和T细胞受体基因重排的分子遗传学分析评估,3例患者在抗-Tac治疗后1至8个月以上出现一过性混合、部分或完全缓解。抗肿瘤作用的确切机制尚不清楚;然而,使用阻止IL-2与ATL细胞上其受体相互作用的单克隆抗体为治疗这种恶性肿瘤提供了合理的方法。
Human T-cell lymphotropic virus I (HTLV-I)-induced adult T-cell leukemia (ATL) cells constitutively express interleukin-2 (IL-2) receptors identified by the anti-Tac monoclonal antibody (MoAb), whereas normal resting cells do not. This observation provided the scientific basis for a trial of intravenous anti-Tac in the treatment of nine patients with ATL. The patients did not suffer untoward reactions and did not have a reduction in the normal formed elements of the blood, and only one of the nine produced antibodies to the anti-Tac MoAb. Three patients had transient mixed, partial, or complete remissions lasting from 1 to more than 8 months after anti-Tac therapy, as assessed by routine hematologic tests, immunofluorescence analysis of circulating cells, and molecular genetic analysis of HTLV-I provirus integration and of the T-cell receptor gene rearrangement. The precise mechanism of the antitumor effects is unclear; however, the use of a MoAb that prevents the interaction of IL-2 with its receptor on ATL cells provides a rational approach for the treatment of this malignancy.
DOI: 10.1182/blood.v65.6.1416.bloodjournal6561416
发表时间: 1985-06
期刊: Blood
影响因子: 20.3
作者:
M. Krönke;J. Depper;W. Leonard;E. Vitetta;T. Waldmann;W. Greene
通讯作者: M. Krönke;J. Depper;W. Leonard;E. Vitetta;T. Waldmann;W. Greene
DOI: 10.1073/pnas.83.24.9694
发表时间: 1986-12-01
影响因子: 11.1
作者:
TSUDO, M;KOZAK, RW;WALDMANN, TA
通讯作者: WALDMANN, TA
DOI: 10.1016/s0022-5347(17)50005-1
发表时间: 1984-03
期刊: Cancer research
影响因子: 11.2
作者:
H. Masui;T. Kawamoto;J. Sato;B. Wolf;G. Sato;J. Mendelsohn
通讯作者: H. Masui;T. Kawamoto;J. Sato;B. Wolf;G. Sato;J. Mendelsohn
使用抗 Tac 单克隆抗体延长灵长类同种异体肾移植物。
DOI: --
发表时间: 1988
期刊: Current surgery
影响因子: --
作者:
Reed,MH;Shapiro,ME;Strom,TB;Milford,EL;Carpenter,CB;Letvin,NL;Waldmann,TA;Kirkman,RL
通讯作者: Kirkman,RL
DOI: 10.1056/nejm198203043060906
发表时间: 1982-01-01
影响因子: 158.5
作者:
MILLER, RA;MALONEY, DG;LEVY, R
通讯作者: LEVY, R